Cim Investment Management Inc Arrowhead Pharmaceuticals, Inc. Transaction History

Cim Investment Management Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 16, 2023	BUY	$23.68 - $38.51 $74,639 - $121,383	3,152 Added 57.35%	8,648 $219,000
Q4 2022 Feb 14, 2023	BUY	$28.0 - $40.56 $153,888 - $222,917	5,496 New	5,496 $222,000
Q2 2022 Sep 02, 2022	SELL	$27.79 - $50.61 $152,733 - $278,152	-5,496 Closed	0 $0
Q1 2022 May 17, 2022	SELL	$39.62 - $69.97 $24,326 - $42,961	-614 Reduced 10.05%	5,496 $253,000
Q4 2021 May 19, 2022	SELL	$58.09 - $82.51 $443,517 - $629,963	-7,635 Reduced 55.55%	6,110 $405,000
Q4 2021 Feb 02, 2022	BUY	$58.09 - $82.51 $354,929 - $504,136	6,110 Added 80.03%	13,745 $882,000
Q1 2021 May 20, 2021	BUY	$61.35 - $90.47 $81,534 - $120,234	1,329 Added 21.08%	7,635 $506,000
Q4 2020 Feb 17, 2021	BUY	$43.82 - $85.37 $5,346 - $10,415	122 Added 1.97%	6,306 $484,000
Q3 2020 Nov 16, 2020	BUY	$33.21 - $51.27 $1,926 - $2,973	58 Added 0.95%	6,184 $266,000
Q2 2020 Aug 14, 2020	BUY	$26.12 - $43.27 $160,011 - $265,072	6,126 New	6,126 $265,000

295

91.1M

155K

426K

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.76B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

Get notified when there are updates to the investment portfolio of Cim Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Cim Investment Management Inc with notifications on news.